Soran Atilla, Tane Kaori, Sezgin Efe, Bhargava Rohit
Division of Breast Surgery and Lymphedema Program, Magee-Womens Hospital of University of Pittsburgh Medical Center, Suite 2601, 300 Halket Street, Pittsburgh, PA, USA.
Division of Breast Surgery, Hyogo Cancer Center, Akashi, Hyogo, Japan.
Eur J Breast Health. 2020 Apr 1;16(2):117-123. doi: 10.5152/ejbh.2020.5338. eCollection 2020 Apr.
Oncotype DX recurrence score (RS) can be predicted from Magee Equations (MS) postoperatively. The aim of this study is to investigate correlation of MS with RS from pretreatment core needle biopsy (CNB) tissues, and their clinical usefulness in prediction of response to neoadjuvant chemotherapy (NCT) in estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer (BC).
Pretreatment CNB tissue samples from 60 patients with ER+/HER2- invasive BC were analyzed for MS and RS correlation. MS and RS were categorized as follows: low (<18), intermediate (18-30), and high (≥ 31). Percentage Tumor size Reduction (%TR) was used to assess tumor response to NCT, and substantial %TR was defined as at least 50% reduction (≥50%TR). Correlation between MS and RS, and predictive factors for the ≥50%TR achievement were assessed.
MS and RS represented a strong correlation (Spearman's correlation; r=0.58, p<0.0001) as a continuous variable. As a categorical variable, the concordance between MS and RS was 43.3%, and it increased to 80% (r=0.61, p=0.003) with the exclusion of the intermediate risk categories. Although, there was pathologic complete response (pCR), MS showed the highest predictive power for the ≥50% TR achievement, none of the factors were statistically significant (p≥0.07).
Our study demonstrated that there was a strong correlation between MS and RS from pretreatment biopsy tissue samples in ER+ and HER2- invasive BC.
术后可根据马吉方程（MS）预测肿瘤类型DX复发评分（RS）。本研究旨在探讨MS与雌激素受体阳性且人表皮生长因子受体2阴性（ER+/HER2-）乳腺癌（BC）患者术前粗针穿刺活检（CNB）组织中RS的相关性，以及它们在预测新辅助化疗（NCT）反应方面的临床实用性。
对60例ER+/HER2-浸润性BC患者的术前CNB组织样本进行MS与RS相关性分析。MS和RS分类如下：低（<18）、中（18 - 30）、高（≥31）。肿瘤大小缩小百分比（%TR）用于评估肿瘤对NCT的反应，显著%TR定义为至少缩小50%（≥50%TR）。评估MS与RS之间的相关性以及实现≥50%TR的预测因素。
作为连续变量，MS与RS呈现出强相关性（斯皮尔曼相关性；r = 0.58，p < 0.0001）。作为分类变量，MS与RS之间的一致性为43.3%，排除中间风险类别后，一致性提高到80%（r = 0.61，p = 0.003）。尽管存在病理完全缓解（pCR），MS对实现≥50%TR显示出最高的预测能力，但没有一个因素具有统计学意义（p≥0.07）。
我们的研究表明，在ER+和HER2-浸润性BC患者的术前活检组织样本中，MS与RS之间存在强相关性。
